BACKGROUND: Irritable bowel syndrome (IBS) is a heterogenous disorder with visceral hypersensitivity as important hallmark. It is not known whether IBS patients with visceral hypersensitivity have different epidemiological and clinical characteristics compared with IBS patients without visceral hypersensitivity. Aim of our study was to compare in detail a large group of hyper- vs normosensitive IBS patients with respect to epidemiological and clinical characteristics. METHODS: IBS patients (Rome III criteria) have been recruited for a large-scale cohort study. All patients from this cohort who underwent a rectal barostat procedure were included and allocated based on those with and without visceral hypersensitivity. Patient demographics, and symptoms were collected using questionnaires (GSRS, HADS, SF-36) and a 14-day symptom diary for IBS-related symptoms. A multivariate logistic regression model was used to identify risk markers for having visceral hypersensitivity. KEY RESULTS: Ninety-five normosensitive and 93 hypersensitive IBS patients participated in this study. Hypersensitive patients had significantly higher scores for GSRS abdominal pain (p < 0.05), indigestion, reflux and constipation syndrome (all p < 0.01), and IBS symptom intensity, discomfort (both p < 0.05) and mean symptom composite score (p < 0.01). Age, female sex, and the use of SSRI medication were significantly different between the normo- and the hypersensitive IBS patients. However, after adjustment for other risk markers, only increasing age was found to be significantly associated with lower odds for having hypersensitivity (OR 0.97 [95% CI: 0.94; 0.99]). CONCLUSIONS & INFERENCES: Apart from more severe symptomatology, hypersensitive IBS patients are characterized by significantly younger age compared with normosensitive IBS patients. The study has been registered in the US National Library of Medicine (http://www.clinicaltrials.gov, NCT00702026).
BACKGROUND:Irritable bowel syndrome (IBS) is a heterogenous disorder with visceral hypersensitivity as important hallmark. It is not known whether IBSpatients with visceral hypersensitivity have different epidemiological and clinical characteristics compared with IBSpatients without visceral hypersensitivity. Aim of our study was to compare in detail a large group of hyper- vs normosensitive IBSpatients with respect to epidemiological and clinical characteristics. METHODS:IBSpatients (Rome III criteria) have been recruited for a large-scale cohort study. All patients from this cohort who underwent a rectal barostat procedure were included and allocated based on those with and without visceral hypersensitivity. Patient demographics, and symptoms were collected using questionnaires (GSRS, HADS, SF-36) and a 14-day symptom diary for IBS-related symptoms. A multivariate logistic regression model was used to identify risk markers for having visceral hypersensitivity. KEY RESULTS: Ninety-five normosensitive and 93 hypersensitiveIBSpatients participated in this study. Hypersensitivepatients had significantly higher scores for GSRS abdominal pain (p < 0.05), indigestion, reflux and constipation syndrome (all p < 0.01), and IBS symptom intensity, discomfort (both p < 0.05) and mean symptom composite score (p < 0.01). Age, female sex, and the use of SSRI medication were significantly different between the normo- and the hypersensitiveIBSpatients. However, after adjustment for other risk markers, only increasing age was found to be significantly associated with lower odds for having hypersensitivity (OR 0.97 [95% CI: 0.94; 0.99]). CONCLUSIONS & INFERENCES: Apart from more severe symptomatology, hypersensitiveIBSpatients are characterized by significantly younger age compared with normosensitive IBSpatients. The study has been registered in the US National Library of Medicine (http://www.clinicaltrials.gov, NCT00702026).
Authors: Sean M P Bennet; Annikka Polster; Hans Törnblom; Stefan Isaksson; Sandrine Capronnier; Aurore Tessier; Boris Le Nevé; Magnus Simrén; Lena Öhman Journal: Am J Gastroenterol Date: 2016-06-07 Impact factor: 10.864
Authors: Mohammad H Farzaei; Roodabeh Bahramsoltani; Mohammad Abdollahi; Roja Rahimi Journal: J Neurogastroenterol Motil Date: 2016-10-30 Impact factor: 4.924
Authors: Zsa Zsa R M Weerts; Lisa Vork; Zlatan Mujagic; Daniel Keszthelyi; Martine A M Hesselink; Joanna Kruimel; Carsten Leue; Jean W M Muris; Daisy M A E Jonkers; Ad A M Masclee Journal: Neurogastroenterol Motil Date: 2019-05-22 Impact factor: 3.598
Authors: Cecilia Grinsvall; Hans Törnblom; Jan Tack; Lukas Van Oudenhove; Magnus Simrén Journal: United European Gastroenterol J Date: 2017-06-20 Impact factor: 4.623
Authors: Zlatan Mujagic; Ettje F Tigchelaar; Alexandra Zhernakova; Thomas Ludwig; Javier Ramiro-Garcia; Agnieszka Baranska; Morris A Swertz; Ad A M Masclee; Cisca Wijmenga; Frederik J van Schooten; Agnieszka Smolinska; Daisy M A E Jonkers Journal: Sci Rep Date: 2016-06-06 Impact factor: 4.379
Authors: Lisa Vork; Daniel Keszthelyi; Sander M J van Kuijk; Emilio G Quetglas; Hans Törnblom; Magnus Simrén; Qasim Aziz; Maura Corsetti; Jan Tack; Zlatan Mujagic; Carsten Leue; Joanna W Kruimel; Ad A M Masclee Journal: Clin Transl Gastroenterol Date: 2020-07 Impact factor: 4.396